Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + levofolinic acid + 5-fluorouracil + oxaliplatin
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
bevacizumab + levofolinic acid + 5-fluorouracil + oxaliplatin is a multi-agent chemotherapy regimen that combines a monoclonal antibody (bevacizumab) targeting vascular endothelial growth factor (VEGF) with the FOLFOX regimen, which includes oxaliplatin (a platinum-based alkylating agent), 5-fluorouracil (an antimetabolite pyrimidine analog), and levofolinic acid (folinic acid, also known as leucovorin, used to enhance the efficacy and reduce toxicity of 5-fluorouracil)[1][2][5]. This regimen is primarily indicated for the first-line treatment of metastatic colorectal cancer (mCRC)[1][2][4]. Bevacizumab inhibits angiogenesis by binding VEGF-A, thus suppressing blood vessel growth in tumors. 5-fluorouracil inhibits thymidylate synthase to block DNA synthesis. Levofolinic acid enhances the binding of 5-fluorouracil to thymidylate synthase. Oxaliplatin induces DNA cross-linking and apoptosis in cancer cells[1][2][5].
- Other names
- FOLFOX + bevacizumab
02
Targets
Beyond the preview
Go deeper on bevacizumab + levofolinic acid + 5-fluorouracil + oxaliplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + levofolinic acid + 5-fluorouracil + oxaliplatin.